1. Market Research
  2. > Pharmaceutical
  3. > Therapy Market Trends
  4. > Competitor Analysis: VEGF & VEGF-R Antibodies 2015 – Biosimilars and Biosuperiors of Avastin and Lucentis

Competitor Analysis: VEGF & VEGF-R Antibodies 2015 – Biosimilars and Biosuperiors of Avastin and Lucentis

This Competitive Intelligence Report about VEGF and VEGF-R Antibodies 2015 - Biosimilars and Biosuperiors of Avastin and Lucentis provides a competitor evaluation in the field of recombinant antibodies targeting vascular endothelial growth factor (VEGF) or its receptors (VEGF-R) used to treat various cancers and ophthalmic diseases as of February 2015. Purchase of the downloadable pdf report includes a 6-month online access to the data of the report and any updates since the publication date. Credentials to access the database will be sent by e-mail and allow online work with the project data to print or export an individual report.

The family of antibody products targeting vascular endothelial growth factor (VEGF) or VEGF receptor (VEGF-R) has become highly successful in clinical and economic terms. Avastin and Lucentis as the first generation products and Eylea and Zaltrap as the second wave of VEGF products followed by the anti-VEGF-R2 antibody Cyramzy generated combined product sales of more than US$ 13.7 bln in the year 2014. Strong driver of sales growth are the pipelines in a product leading to approval in more and more cancer and eye disease indications.

The commercial success of the VEGF antibodies and the expiry of patent protection has laid the ground for development of second generation "biobetter or biosuperior" molecules as well as of biosimilar copies of the originator products with the most advanced molecules already in phase III trials.

The report includes a compilation of currently active projects in development of VEGF and VEGF-R targeting antibodies for treatment of cancer and neo-angiogenic eye diseases. In addition, the report lists company-specific R&D pipelines of VEGF antibodies. Competitor projects are listed in a tabular format providing information on:

Drug Codes, Target / Mechanism of Action, Class of Compound, Company, Product Category, Indication, R&D Stage and additional comments with a hyperlink leading to the source of information.

About Competitor Analysis Series:

The Competitor Analysis Series delivers NO-FRILLS, but concise information about the pipeline of R&D projects for targets, diseases, technologies and companies at low prices. The information is provided in a tabular format and fully referenced.

Table Of Contents

Competitor Analysis: VEGF and VEGF-R Antibodies 2015 - Biosimilars and Biosuperiors of Avastin and Lucentis
Competitor Analysis: VEGF and VEGF-R Antibodies 2015 - Biosimilars and Biosuperiors of Avastin and Lucentis

Table of Contents

1) Marketed VEGF and VEGF-R Antibodies in Oncology:

- Avastin Sales and Pipeline-
- Zaltrap Sales and Pipeline-
- Cyramza Sales and Pipeline-

2) Avastin and Zaltrap Biosuperiors:

- Anti-VEGF Pipeline in Oncology-
- Bispecific Anti-VEGF and Antibody Combination Antibody Pipeline in Oncolgy-

3) Cyramza Biosuperiors:

- Anti-VEGF-R and Antibody Combination Pipeline-
- Bispecific Anti-VEGF-R Antibody Pipeline-


4) Avastin Biosimilar Pipeline

5) Marketed VEGF Antibodies in Ophthalmology

- Lucentis Sales and Pipeline-
- Eylea Sales and Pipeline-

6) Biosuperior Lucentis and Eylea Pipeline:

- Anti-VEGF Antibody Pipeline in Ophthalmology-
- Bispecific Anti-VEGF and Antibody Combination Pipeline in Ophthalmology-

7) Lucentis Biosimilar Pipeline
8) Corporate VEGF and VEGF-R Antibody Biosimilar and Biosuperior Pipelines

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Ahmad

+1 718 618 4302

Purchase Reports From Reputable Market Research Publishers
Colorectal Cancer KOL Insight 2016

Colorectal Cancer KOL Insight 2016

  • $ 8085
  • Industry report
  • October 2016
  • by Firstword Pharma

KOLs embrace novel MoAs as low survival rates drive search for new treatments Faced with persistently low survival rates, KOLs are calling for new approaches to treat late-stage colorectal cancer (CRC). ...

Sunitinib Malate Market: By Disease (Pancreatic Neuroendocrine Tumors & Kidney Cancer) & By Region (Europe, North America, Asia-Pacific & Rest of the World (RoW))-Forecast (2016-2021)

Sunitinib Malate Market: By Disease (Pancreatic Neuroendocrine Tumors & Kidney Cancer) & By Region (Europe, North America, Asia-Pacific & Rest of the World (RoW))-Forecast (2016-2021)

  • $ 5250
  • Industry report
  • September 2016
  • by Industry ARC

Sunitinib, developed and marketed as Sutent by Pfizer Inc and previously known as SU11248, is a small-molecule medicine which has to be administered orally and has been proven to be effective in blocking ...

Gastric Cancer Therapeutics in Asia-Pacific Markets to 2022 - Growth Driven by Increasing Prevalence and Launch of Targeted Therapies

Gastric Cancer Therapeutics in Asia-Pacific Markets to 2022 - Growth Driven by Increasing Prevalence and Launch of Targeted Therapies

  • $ 4995
  • Industry report
  • September 2016
  • by GBI Research

Gastric Cancer Therapeutics in Asia-Pacific Markets to 2022 - Growth Driven by Increasing Prevalence and Launch of Targeted Therapies Summary Gastric cancer is characterized by the formation of malignant ...


ref:plp2015

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.